United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

United Therapeutics Stock Down 1.5%

Shares of UTHR stock traded down $8.14 during trading hours on Thursday, reaching $521.00. The company’s stock had a trading volume of 436,972 shares, compared to its average volume of 491,227. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The firm’s 50 day simple moving average is $534.23 and its 200-day simple moving average is $537.17. The company has a market capitalization of $22.35 billion, a price-to-earnings ratio of 18.64, a PEG ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the firm earned $6.41 EPS. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Analysts Set New Price Targets

UTHR has been the subject of a number of research reports. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Weiss Ratings upgraded shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in UTHR. BlackRock Inc. bought a new position in shares of United Therapeutics during the second quarter valued at $2,868,735,000. Wellington Management Group LLP grew its stake in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Jupiter Topco LLC acquired a new stake in United Therapeutics in the second quarter valued at $450,140,000. Norges Bank acquired a new stake in United Therapeutics in the fourth quarter valued at $293,418,000. Finally, Avoro Capital Advisors LLC increased its holdings in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.